Zealand Pharma A/S - Announcement of transactions in the company’s shares and related securities by executives and their related parties


Copenhagen, 2013-05-23 10:24 CEST (GLOBE NEWSWIRE) -- Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S (“Zealand”) shall announce transactions in the company’s shares and related securities by executives and persons/companies closely related to them.

In this regard, Zealand announces the following transaction:                                     

Name: Jørgen Lindegaard
Reason: Vice chairman of the Board
Issuer: Zealand Pharma A/S
Type Shares
ISIN code: DK0060257814
Transaction: Purchase
Trading date: 22 May 2013
Market: NASDAQ OMX København A/S
Amount: 3,600
Price: DKK 75.50
Market value: DKK 271,800.00

 

Hereafter, Jørgen Lindegaard owns 14,285 shares in Zealand.

***

 

 

For further information, please contact:

 

David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications - Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

 

About Zealand

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved in Europe (February 2013) under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA filed in Dec 2012) and Japan (NDA filed in June 2012).

 

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury. For further information: www.zealandpharma.com  


Attachments

03-13_0523 - Executives trading - UK.pdf